Summary
In order to evaluate the gastric tolerance of the new piroxicam formulation CHF 1194 (piroxicam complexed with beta-cyclodextrin), a double-blind randomized trial was carried out in 21 young healthy volunteers comparing CHF 1194 with piroxicam and placebo.
Faecal blood loss measurement by the Cr-51 labelled red blood cell technique, upper gastrointestinal endoscopic evaluation, titration of gastric pH and gastric biopsies before, during and after treatment were used to assess drug tolerability.
Four out of 7 volunteers in the piroxicam-treated group withdrew because of severe gastrointestinal symptoms and oesophageal and/or gastroduodenal lesions, while all subjects treated with CHF 1194 or placebo completed the treatment. There was a significant difference between the endoscopic scores of the piroxicam and placebo groups, whereas no differences were found between CHF 1194 and placebo, nor between piroxicam and CHF 1194.
Daily mean gastrointestinal blood loss was greater in the piroxicam group than in either the CHF 1194 or placebo groups, but the difference was not significant, due to the small number of piroxicam-treated subjects who completed the study.
When administered for a short period to healthy young subjects, CHF 1194 caused less gastric damage and was better tolerated than piroxicam.
Similar content being viewed by others
References
Del Favero A (1988) Anti-inflammatory analgesics and drugs used in rheumatoid arthritis and gout. In: Dukes MNG (ed) Side-effects of drugs. Elsevier, Amsterdam, Annal 12: 79–100
Stadler-Szöke A, Szejtly J (1981) A forecast for application of cyclodextrins in the Pharmaindustry. In: J. Szejtly (ed) Proc 1st Int Symp on cyclodextrins, Budapest. Reidel Publ, Dordrecht Holland, pp 377–387
Lanza F, Panagides J, Salom I (1986) Etodolac compared with aspirin: An endoscopic study of the gastrointestinal tracts of normal volunteers. J Rheumatol 13: 299–303
Frenkel EP, McCall MS, Douglass CC, Eisenberg S (1968) Fecal blood loss following aspirin and coated aspirin microspherule administration. J Clin Pharmacol 8: 347–351
Lehtola J, Sipponen P (1977) A gastroscopic and histological double-blind study of the effects of diclofenac sodium and naproxen on the human gastric mucosa. Scand J Rheumatol 6: 97–102
Daftson AC, Johnson EL, Keely FJ, Gryczko Rawski V (1984) High performance liquid cromatographic analysis of isoxicam in human plasma and urine. J Cromatogr 305: 145–151
Kevin JI (1988) Mechanisms of nonsteroidal anti-inflammatory drugs-induced gastric damage. Am J Med 84 (2A): 41–48
Redfern JS, Lee E, Feldman M (1987) Effect of indomethacin on gastric mucosal prostaglandins in humans. Gastroenterology 92: 969–977
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Patoia, L., Clausi, G., Farroni, F. et al. Comparison of faecal blood loss, upper gastrointestinal mucosal integrity and symptoms after piroxicam beta-cyclodextrin, piroxicam and placebo administration. Eur J Clin Pharmacol 36, 599–604 (1989). https://doi.org/10.1007/BF00637743
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00637743